Top Page
Edwards Lifesciences
(NYSE:EW)
Edwards Lifesciences (EW) vs. SPDR S&P 500 ETF (SPY)
Edwards Lifesciences Business Overview & Revenue Model
Edwards Lifesciences Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where Edwards Lifesciences is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataEdwards Lifesciences Earnings Call Summary
Edwards Lifesciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.88B | 5.44B | 5.01B | 5.38B | 5.23B | 4.39B |
| Gross Profit | 4.60B | 4.32B | 3.97B | 4.22B | 4.01B | 3.29B |
| EBITDA | 1.74B | 1.72B | 1.53B | 1.96B | 1.89B | 1.07B |
| Net Income | 1.36B | 4.17B | 1.40B | 1.52B | 1.50B | 823.40M |
Balance Sheet | ||||||
| Total Assets | 13.27B | 13.06B | 9.36B | 8.29B | 8.50B | 7.24B |
| Cash, Cash Equivalents and Short-Term Investments | 3.84B | 3.98B | 1.63B | 1.22B | 1.47B | 1.40B |
| Total Debt | 700.30M | 700.00M | 685.10M | 691.30M | 690.30M | 694.90M |
| Total Liabilities | 3.07B | 2.99B | 2.64B | 2.49B | 2.67B | 2.66B |
| Stockholders Equity | 10.21B | 10.00B | 6.65B | 5.81B | 5.84B | 4.57B |
Cash Flow | ||||||
| Free Cash Flow | 804.20M | 289.90M | 629.50M | 953.40M | 1.40B | 647.00M |
| Operating Cash Flow | 1.02B | 542.30M | 895.80M | 1.22B | 1.73B | 1.05B |
| Investing Cash Flow | -1.09B | 2.31B | 173.80M | 252.30M | -1.72B | -531.10M |
| Financing Cash Flow | -916.80M | -983.00M | -711.00M | -1.58B | -356.30M | -486.90M |
Edwards Lifesciences Technical Analysis
Edwards Lifesciences Risk Analysis
Edwards Lifesciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $49.66B | 36.66 | 13.59% | ― | 0.19% | 65.58% | |
79 Outperform | $152.23B | 54.92 | 12.66% | ― | 21.62% | 54.80% | |
77 Outperform | $227.08B | 16.38 | 30.62% | 1.81% | 6.37% | 142.39% | |
70 Outperform | $138.52B | 47.56 | 14.04% | 0.93% | 10.95% | -18.32% | |
69 Neutral | $22.64B | 32.31 | 30.63% | ― | 14.21% | 5.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $9.66M | -0.61 | -207.19% | ― | -5.19% | -0.81% |
Edwards Lifesciences Corporate Events
Edwards Lifesciences Corp. recently held its earnings call, revealing a robust quarterly performance that was generally well-received by investors. The company reported significant sales growth across various segments and increased its full-year guidance, buoyed by positive clinical data presentations. However, some concerns were noted regarding declining gross profit margins and upcoming changes in financial leadership.
Edwards Lifesciences Corporation is a global leader in structural heart innovations, specializing in transcatheter heart valve therapies and surgical heart valve replacement and repair. The company is renowned for its commitment to improving patient outcomes through advanced medical technologies.
On October 30, 2025, Edwards Lifesciences announced that its Chief Financial Officer, Scott Ullem, will transition from his role by mid-year 2026. The company has started a selection process for a new CFO, ensuring continuity and a smooth transfer of responsibilities, with Ullem continuing in an advisory role post-transition.
The most recent analyst rating on (EW) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Study Overview: Edwards Lifesciences Corp. is currently conducting an early feasibility study titled TVMR With the INNOVALVE System Trial – Early Feasibility Study. The primary goal of this study is to assess the safety and performance of the INNOVALVE system in treating patients with degenerative or functional mitral valve regurgitation. This study is significant as it could potentially lead to advancements in treatment options for this condition.
Study Overview: Edwards Lifesciences Corp. is conducting the PROGRESS Trial, officially titled ‘The PROGRESS Trial: A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement.’ The study aims to evaluate the safety and effectiveness of the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in patients with moderate, calcific aortic stenosis. This research is significant as it could influence treatment protocols for this condition.
Study Overview: Edwards Lifesciences Corp. is conducting a study titled Continuous Blood Pressure Monitoring During Outpatient Surgery, known as The Continuity Study. The primary objective is to compare intermittent blood pressure measurement using an oscillometric arm cuff with continuous noninvasive blood pressure measurement using VitaWave finger cuffs in patients undergoing elective outpatient surgery. This study is significant as it aims to enhance the accuracy and efficiency of blood pressure monitoring during surgical procedures.
Edwards Lifesciences Corp. is conducting a pivotal clinical trial titled ‘A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation.’ The study aims to assess the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with severe tricuspid regurgitation who are at an intermediate or greater risk of mortality from surgery.
Study Overview: The ENCIRCLE Trial, officially titled ‘SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access,’ aims to establish the safety and effectiveness of the SAPIEN M3 System for patients with symptomatic mitral regurgitation (MR) who are not suitable for existing surgical or transcatheter treatments. This study is significant as it addresses a critical gap in treatment options for this patient group.
Edwards Lifesciences Corp. is conducting a study titled ‘Post-Market Clinical Follow-up Study of Edwards Lifesciences MITRIS RESILIA Mitral Valve in Chinese Population.’ The study aims to gather data on the acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, particularly for patients needing mitral valve replacement. This research is significant as it could influence future medical practices and product offerings in the cardiovascular field.
Edwards Lifesciences Corp. has initiated the HemoSphere Alta Clinical Development Study, a prospective, non-randomized single arm study aimed at enhancing the HemoSphere Alta Advanced Monitoring Platform. This study targets adult subjects experiencing hemodynamic instability, with data collected to support ongoing device development.
Edwards Lifesciences Corp. is conducting a study titled ‘A Prospective, Observational Registry Study Designed to Collect Real-world Hemodynamic and Clinical Outcomes of the INSPIRIS RESILIA Aortic Valve.’ The study aims to gather real-world data on the performance and outcomes of the INSPIRIS RESILIA Aortic Valve in patients undergoing aortic valve replacement. This research is significant as it provides insights into the valve’s effectiveness in practical settings.
Edwards Lifesciences Corp. is conducting the ALT-FLOW II Trial, officially titled ‘A Randomized, Sham-controlled Clinical Trial for Evaluation of the Edwards APTURE Transcatheter Shunt System.’ The study aims to assess the effectiveness of the APTURE Transcatheter Shunt System in treating heart failure, a significant health concern worldwide. This trial is crucial as it could offer a new treatment avenue for patients with heart failure, potentially improving quality of life and reducing healthcare costs.
Study Overview: Edwards Lifesciences Corp. is conducting a study titled ‘Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves.’ The study aims to evaluate the safety and effectiveness of the SAPIEN X4 Transcatheter Heart Valve in patients with failing aortic bioprosthetic valves who are at high or greater risk, addressing critical conditions like aortic valve insufficiency and stenosis.
Edwards Lifesciences Corp. is currently conducting a study titled ‘Assessing for Personalized Blood Pressure Targets During Cardiopulmonary Bypass With the Proprietary Cerebral Adaptive Index: A Pilot Investigation.’ This pilot study aims to evaluate the effectiveness of the Cerebral Adaptive Index (CAI) in determining personalized blood pressure targets during cardiopulmonary bypass, which could significantly enhance patient outcomes by tailoring treatment to individual needs.
Study Overview: The ALTERRA Post-Approval Study, officially titled ‘Multicenter Post-Approval Study of Congenital Pulmonic Valve Dysfunction Studying the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System With Alterra Adaptive Prestent,’ aims to monitor device performance and outcomes in patients with congenital heart defects. This study is significant as it evaluates the real-world effectiveness of a novel valve system in treating conditions like pulmonary valve insufficiency and complex congenital heart defects.
Study Overview: The MiCLASP Post Market Clinical Follow-Up (PMCF) Study, officially titled ‘Transcatheter Repair of Mitral Regurgitation With Edwards PASCAL Transcatheter Valve Repair System: A European Prospective, Multicenter Post Market Clinical Follow-Up (PMCF),’ aims to evaluate the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in treating mitral regurgitation and insufficiency. This study is significant as it provides critical post-market data on a key medical device used in heart valve repair.
Edwards Lifesciences Corp. is currently conducting a study titled ‘Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve.’ The study aims to gather real-world data on the safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in patients needing mitral valve replacement. This research is significant as it seeks to provide insights into both acute and long-term outcomes for individuals with mitral stenosis or mitral valve insufficiency.
Edwards Lifesciences Corp. is collaborating with World Health Research Inc. on a study titled ‘A Prospective Cohort Study of Bicuspid Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm for Sapien 3 Balloon Expandable Valve.’ The study aims to evaluate the impact of the ABC Bicuspid Sizing Algorithm on clinical outcomes for patients with bicuspid aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Key objectives include assessing technical success post-procedure and device success 30 days after the procedure.
Edwards Lifesciences Corp. is conducting a pivotal clinical trial titled Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF). The study aims to evaluate the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System compared to the Abbott MitraClip in patients with mitral regurgitation, a condition where the heart’s mitral valve doesn’t close tightly, allowing blood to flow backward in the heart.
Edwards Lifesciences Corp. is conducting a study titled ‘Transcatheter Tricuspid Valve Replacement (TTVR) in Patients With Severe TR ONgoing Evidence Generation (STRONG) Under Coverage With Evidence Development (CED)’. The study aims to evaluate the long-term health outcomes of patients with severe Tricuspid Regurgitation who have undergone the TTVR procedure using the EVOQUE system. This research is significant as it could provide crucial data on the effectiveness of this treatment.
Study Overview: Edwards Lifesciences Corp. is conducting a study titled ‘Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve – Mitral’. The study aims to evaluate the safety and effectiveness of the SAPIEN X4 Transcatheter Heart Valve (THV) in patients at high surgical risk with failing mitral valves. This research is significant as it addresses critical needs in treating complex mitral valve conditions.
Edwards Lifesciences Corp. is conducting a clinical study titled ‘COngenital Multicenter Trial of Pulmonic vAlve Dysfunction Studying the SAPIEN 3 interventIONal THV’. The study aims to evaluate the safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve (THV) systems in patients with pulmonary valve dysfunction. This research is significant as it targets complex congenital heart defects and pulmonary valve issues, offering potential advancements in treatment options.
Edwards Lifesciences Corp. is conducting a study titled ‘Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Real World European Investigation of Safety and Clinical Efficacy Using a Novel Device’ (TRISCEND III EU). The study aims to assess the safety and clinical efficacy of the Edwards EVOQUE system, a transcatheter tricuspid valve replacement device, in real-world settings across Europe. This investigation is significant as it addresses tricuspid valve regurgitation and other cardiovascular diseases, potentially offering a less invasive treatment option.
On August 19, 2025, Edwards Lifesciences Corporation announced its entry into an accelerated share repurchase agreement, which may impact its financial strategies and shareholder value.
The most recent analyst rating on (EW) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Edwards Lifesciences Corp. is conducting the TRISCEND II Pivotal Trial to assess the safety and effectiveness of the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement system. This study aims to provide a novel treatment option for patients with severe tricuspid regurgitation by comparing the EVOQUE system combined with optimal medical therapy (OMT) against OMT alone.
The ENCIRCLE Trial, officially titled ‘SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access,’ aims to evaluate the safety and effectiveness of the SAPIEN M3 System for patients with symptomatic mitral regurgitation (MR) unsuitable for existing surgical or transcatheter treatments. This study is significant as it addresses a critical need for alternative treatment options in this patient population.
Edwards Lifesciences Corp. is conducting the 2019-06 TRISCEND Study to evaluate the safety and clinical efficacy of the Edwards EVOQUE Tricuspid Valve Replacement System. This prospective, multi-center study aims to assess the device’s performance in replacing the tricuspid valve through a transcatheter approach, which could significantly impact patient outcomes with tricuspid valve disease.
Study Overview: Edwards Lifesciences Corp. is conducting a study titled ‘Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve’ to evaluate the safety and effectiveness of the SAPIEN X4 Transcatheter Heart Valve in patients with severe aortic stenosis. This study is significant as it aims to provide a less invasive treatment option for this condition.
Edwards Lifesciences Corp. is conducting the ALT-FLOW II Trial, officially titled ‘A Randomized, Sham-controlled Clinical Trial for Evaluation of the Edwards APTURE Transcatheter Shunt System.’ The study aims to evaluate the safety, performance, and effectiveness of the Edwards APTURE transcatheter shunt system in treating patients with heart failure with preserved or mildly reduced ejection fraction who remain symptomatic despite standard medical therapy.
On August 6, 2025, Edwards Lifesciences announced that the U.S. Federal Trade Commission has moved to block its proposed acquisition of JenaValve Technology. Edwards disagrees with this decision, believing it limits treatment options for aortic regurgitation patients and plans to continue pursuing regulatory approval. Despite the FTC’s action, Edwards has revised its full-year 2025 financial guidance, increasing its adjusted EPS forecast to the high-end of $2.45-$2.55, with minimal impact on Q3 guidance.
The most recent analyst rating on (EW) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.